108 completed, 15 recruiting, 10 unknown, 9 withdrawn. 167 Phase 3, 10 Phase 2.
Follow Atopic Dermatitis: new trials by email Literature Review of Atopic Dermatitis trials Research Report on Atopic Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Pfizer | 90 | 2027-05-01 | 2026-09-16 |
| A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Almirall, S.A. | 230 | 2026-11-01 | 2026-10-14 |
| Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis Roflumilast Cream 0.3%, Vehicle Cream - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 3 | Recruiting | Arcutis Biotherapeutics, Inc. | 415 | 2026-10-30 | 2026-11-06 |
| Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Nemolizumab 30 mg, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Galderma R&D | 240 | 2026-10-08 | 2026-10-16 |
| A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis Dupilumab Injection, IBI3027 - Atopic Dermatitis | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 520 | 2026-09-15 | 2026-10-15 |
| Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis ADSTEM Inj., Placebo - Atopic Dermatitis | Phase 3 | Recruiting | EHL Bio Co., Ltd. | 286 | 2026-09-15 | 2026-11-13 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Tilrekimig, Dupilumab, Placebo for Tilrekimig - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 1375 | 2026-08-24 | 2026-11-06 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema Tilrekimig, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 375 | 2026-08-17 | 2026-11-12 |
| Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis Crisaborole 2%, Tacrolimus 0.1% - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Shalamar Institute of Health Sciences | 66 | 2026-06-01 | 2025-09-09 |
| Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis VC005, VC005 Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 360 | 2026-05-12 | 2026-07-07 |
| A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis MG-K10 Humanized Monoclonal Antibody Injection - Atopic Dermatitis, Atopic Eczema | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 498 | 2026-05-01 | 2026-03-18 |
| A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis Tapinarof cream, 1%, Vehicle Cream - Atopic Dermatitis | Phase 3 | Active not recruiting | Organon and Co | 187 | 2025-12-29 | 2026-11-10 |
| A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema Abrocitinib - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 450 | 2025-12-02 | 2026-11-05 |
| A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis Stapokibatrt - Atopic Dermatitis | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 240 | 2025-09-01 | 2025-08-06 |
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) GX-03, Vehicle - Eczema Atopic Dermatitis, Eczema | Phase 2 / Phase 3 | Recruiting | Turn Therapeutics | 190 | 2025-07-11 | 2026-09-04 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Ruxolitinib, Vehicle Cream - Atopic Dermatitis | Phase 3 | Active not recruiting | Incyte Corporation | 159 | 2025-06-17 | 2026-08-19 |
| Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis 1.5% QLM3003 ointment, 2% QLM3003 ointment, QLM3003 Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 360 | 2025-05-16 | 2025-08-26 |
| Study of Stapokibatrt in Children Subjects With Atopic Dermatitis Stapokibatrt, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 240 | 2025-05-01 | 2025-05-04 |
| A Phase Ⅲ Comparative Study of QL2108 to Dupixent® QL2108 injection, Dupixent® - Atopic Dermatitis | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 520 | 2025-04-01 | 2025-03-21 |
| Herbal Ointment in Treating Atopic Dermatitis Topically herbal ointment, Placebo - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Recruiting | En Chu Kong Hospital | 66 | 2025-03-01 | 2025-02-27 |
Showing 20 of 167. Sign in to see all of them.
Dermatitis, Atopic (167) · Eczema (55) · Dermatitis (16) · Skin Diseases (13) · Pruritus (11) · Skin Diseases, Eczematous (5) · Skin Diseases, Genetic (5) · Immune System Diseases (4) · Hypersensitivity (3) · Asthma (2) · Exanthema (2) · Genetic Diseases, Inborn (2) · Hypersensitivity, Immediate (2) · Conjunctivitis, Allergic (1) · Facies (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (167) · Skin and Connective Tissue Diseases (167) · Genetic Diseases, Inborn (165) · Hypersensitivity, Immediate (165) · Hypersensitivity (164) · Immune System Diseases (163) · Skin Diseases, Eczematous (162) · Skin Diseases, Genetic (162) · Skin Diseases (154) · Dermatitis (151) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (11) · Skin Manifestations (11) · Bronchial Diseases (2) · Lung Diseases (2)
dupilumab (15) · lebrikizumab (14) · Adrenal Cortex Hormones (11) · upadacitinib (11) · tralokinumab (10) · baricitinib (8) · pimecrolimus (8) · abrocitinib (5) · difamilast (4) · Exercise (3) · Desonide (2) · KHK4083 (2) · crisaborole (2) · ruxolitinib (2) · 5-Methoxypsoralen (1)
Eli Lilly and Company (20) · AbbVie (11) · Pfizer (11) · LEO Pharma (10) · Amgen (8) · Fougera Pharmaceuticals Inc. (5) · Incyte Corporation (5) · Keymed Biosciences Co.Ltd (5) · Regeneron Pharmaceuticals (5) · Organon and Co (4) · Almirall, S.A. (3) · Novartis (3) · Otsuka Pharmaceutical Co., Ltd. (3) · Sanofi (3) · Acrotech Biopharma Inc. (2)
United States (75) · Canada (49) · Germany (45) · Poland (43) · Japan (39) · China (38) · Spain (36) · France (29) · Australia (28) · Italy (27) · South Korea (27) · United Kingdom (27) · Taiwan (23) · Hungary (22) · Czechia (20)
Angela C Kaplan (4) · Diana Villalobos (3) · Osamu Sato (3) · Dr. Nikhil Sawant (2) · Jason Wu (2)
PMID 33826132, PMID 36255569, PMID 36749121, PMID 39588375, PMID 40555305, PMID 41118053, PMID 34275122, PMID 34688290, PMID 35714786, PMID 36152216, PMID 36754548, PMID 37043227, PMID 37247226, PMID 38777187, PMID 39110139, PMID 39441580, PMID 40085349, PMID 40383273, PMID 40457140, PMID 40600584, PMID 40875187, PMID 40900410, PMID 41206702, PMID 42530735, PMID 31066001, PMID 33000465, PMID 33165005, PMID 33222559, PMID 33453450, PMID 33658996, PMID 33899152, PMID 33957195, PMID 33982267, PMID 34023008, PMID 34142350, PMID 35262646, PMID 35636689, PMID 36264430, PMID 36525340, PMID 36723913, PMID 36808602, PMID 36920778, PMID 36994947, PMID 37682422, PMID 37804473, PMID 38528257, PMID 38679419, PMID 38696027, PMID 38698175, PMID 38700646
2017 (9), 2018 (8), 2019 (7), 2023 (5), 2025 (3), 2016 (2), 2014 (1), 2015 (1)